104 related articles for article (PubMed ID: 6137249)
1. Growth hormone responses to graded doses of apomorphine HCl in schizophrenia.
Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
Biol Psychiatry; 1983 Aug; 18(8):875-85. PubMed ID: 6137249
[TBL] [Abstract][Full Text] [Related]
2. Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients.
Müller-Spahn F; Modell S; Ackenheil M; Brachner A; Kurtz G
J Psychiatr Res; 1998; 32(5):265-71. PubMed ID: 9789204
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone responses to apomorphine HCl in schizophrenic patients on drug holidays and at relapse.
Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Dermer SW; MacCrimmon DJ; Mitton J
Br J Psychiatry; 1983 May; 142():482-8. PubMed ID: 6135481
[TBL] [Abstract][Full Text] [Related]
4. Predictors of response to clozapine.
Lieberman JA; Kane JM; Safferman AZ; Pollack S; Howard A; Szymanski S; Masiar SJ; Kronig MH; Cooper T; Novacenko H
J Clin Psychiatry; 1994 Sep; 55 Suppl B():126-8. PubMed ID: 7961556
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal instability of hormone responses in schizophrenia.
Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):545-9. PubMed ID: 6686692
[TBL] [Abstract][Full Text] [Related]
6. Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients.
Zemlan FP; Hirschowitz J; Garver DL
Arch Gen Psychiatry; 1986 Dec; 43(12):1162-7. PubMed ID: 3778112
[TBL] [Abstract][Full Text] [Related]
7. Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: preliminary findings.
Szymanski S; Lieberman J; Pollack S; Safferman A; Munne R; Umbricht D; Kane J; Kronig M; Chakos M; Cooper T
Biol Psychiatry; 1995 Jan; 37(1):52-5. PubMed ID: 7893860
[No Abstract] [Full Text] [Related]
8. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
Kolakowska T; Gelder M; Fraser S
Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
[TBL] [Abstract][Full Text] [Related]
9. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
Meltzer HY; Lee MA; Jayathilake K
Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine findings in the schizophrenias.
Garver DL
Endocrinol Metab Clin North Am; 1988 Mar; 17(1):103-9. PubMed ID: 2897906
[TBL] [Abstract][Full Text] [Related]
11. Interictal psychoses in comparison with schizophrenia--a prospective study.
Tadokoro Y; Oshima T; Kanemoto K
Epilepsia; 2007 Dec; 48(12):2345-51. PubMed ID: 17666070
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal growth hormone studies in schizophrenia.
Brown GM; Cleghorn JM; Kaplan RD; Szechtman H; Brown PJ; Szechtman B; Mitton J
Psychiatry Res; 1988 May; 24(2):123-36. PubMed ID: 3406233
[TBL] [Abstract][Full Text] [Related]
13. Relationship of psychotic symptom clusters in schizophrenia to neuroleptic treatment and growth hormone response to apomorphine.
Zemlan FP; Hirschowitz J; Sautter F; Garver DL
Psychiatry Res; 1986 Jul; 18(3):239-55. PubMed ID: 2875478
[TBL] [Abstract][Full Text] [Related]
14. Platelet monoamine oxidase and the growth hormone response to apomorphine in schizophrenia.
Malas KL; van Kammen DP; deFraites EA; Brown GM; Gold PW
Biol Psychiatry; 1983 Feb; 18(2):255-9. PubMed ID: 6830934
[No Abstract] [Full Text] [Related]
15. Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation.
Brambilla F; Bellodi L; Perna G; Arancio C; Bertani A
Biol Psychiatry; 1997 Nov; 42(10):889-97. PubMed ID: 9359974
[TBL] [Abstract][Full Text] [Related]
16. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Kopala LC; Fredrikson D; Good KP; Honer WG
Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
[No Abstract] [Full Text] [Related]
17. Noradrenergic and dopaminergic interrelation in schizophrenia.
Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
[TBL] [Abstract][Full Text] [Related]
18. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
[TBL] [Abstract][Full Text] [Related]
19. [Neuroendocrinology and schizophrenia research].
Müller-Spahn F
Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 64():1-96. PubMed ID: 1682802
[No Abstract] [Full Text] [Related]
20. Reduced growth hormone response to apomorphine in schizophrenic patients with poor premorbid social functioning.
Malas KL; van Kammen DP; de Fraites EA; Brown GM; Gold PW
J Neural Transm; 1987; 69(3-4):319-24. PubMed ID: 3625198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
